Clinical Research Directory
Browse clinical research sites, groups, and studies.
Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission
Sponsor: University Health Network, Toronto
Summary
Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in clinical kidney transplantation. Donor kidneys will be treated on the EVOP system with SYN002 in order to decrease the burden of latent CMV in the organ and mitigate the transmission of cytomegalovirus (CMV).
Official title: Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission: A Safety Trial in Kidney Transplant Recipients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-03-16
Completion Date
2027-12-31
Last Updated
2026-03-23
Healthy Volunteers
No
Interventions
SYN002
SYN002, a fusion protein targeting US28, a human cytomegalovirus (CMV) - specific virally encoded receptor expressed on both latent and lytic CMV-infected cells.
Locations (1)
University Health Network, Toronto General Hospital, Ajmera Transplant Centre
Toronto, Ontario, Canada